Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | SCD highlights from EHA 2023: the biology of pain crises & Solace-kids

Rabi Hanna • 11 Jun 2023
EHA 2023
Non-Malignant Sickle Cell Disease Antibodies Crizanlizumab
Solace-kids

Rabi Hanna, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, shares some of his highlights in sickle cell disease (SCD) from this year’s EHA meeting, commenting on the role of the complement and mastocytes in pain crises, and on the Solace-kids study (NCT03474965) evaluating crizanlizumab in pediatric patients with SCD. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rabi Hanna

0:55
Improving the quality of care for SCD patients transitioning from pediatric to adult
Rabi Hanna • 11 Dec 2023
1:10
Gene therapy for SCD: unanswered questions
Rabi Hanna • 11 Dec 2023
1:55
The promise of gene therapies in SCD and important practical considerations for these agents
Rabi Hanna • 11 Dec 2023
2:34
RUBY & EdiTHAL trials: evaluating the safety and efficacy of EDIT-301 in SCD & thalassemia
Rabi Hanna • 11 Dec 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals